Two Berlin research teams led by Marie-Laure Yaspo at the Max Planck Institute for Molecular Genetics and Hans Lehrach at Alacris Theranostics GmbH in Berlin are partners in the TREGeneration consortium. Their goal is to develop new strategies for the treatment of Graft versus Host Disease, a serious complication following bone marrow transplantation. A total of 6 million euros was awarded to the consortium to perform a 5-year research project comprising a set of five parallel clinical trials.
Transplantation of stem cells can save the life of patients suffering from leukemia or other blood diseases. Between 30 and 50% of patients undergoing stem cell transplantation suffer from graft versus host disease, a potentially serious condition that results from donor immune cells "attacking" patient tissues like skin, internal organs and mucosa. The TREGeneration project aims to test a cell-based therapeutic approach, expected to result in fewer side effects than the pharmacological strategies currently available.
The project is centered on five clinical trials conducted in parallel by five groups in different European countries. In each trial, patients will be treated with a particular blood cell population called regulatory T cells purified from blood of the original bone marrow donor. These cells have the capacity to suppress the tissue damage caused by T cells from the transplanted bone marrow. These early clinical trials (phase I/II) aim to identify the safe dose to be administered and also to generate preliminary efficacy data.
The task of the Berlin groups of Marie-Laure Yaspo at the Max Planck Institute for Molecular Genetics and Hans Lehrach from Alacris Theranostics GmbH is to characterize the “deep immune status” of patients and donors with a new technology developed by the two groups themselves.
Using next generation sequencing, the scientists will analyze the T cell receptor repertoires in the donor and patient samples at several times after treatment in order to track the fate of individual T cell clones and populations during the clinical trials. The results are expected to contribute to a better understanding of the immune suppressive effects of the regulatory T cell treatment on the patients.
The TREGeneration consortium is led by João Lacerda’s team at the Instituto de Medicina Molecular in Lisbon, Portugal, and comprises eight partners from five European countries. The clinical trials will be run independently by each center and are led by proejct participants: João Forjaz de Lacerda at the Hospital de Santa Maria in Lisbon; Matthias Edinger at the Universitätsklinik in Regensburg, Germany; Frédéric Baron at the Laboratory of Cell and Gene Therapy, Sart-Tilman in Liège, Belgium; and Mario Arpinati at the Department of Hematology “Seràgnoli”, University Hospital S.Orsola-Malpighi, Bologna, Italy.
The data generated by the different clinical trials will be integrated within the framework of the statistical analysis performed by Marta García-Fiñana’s team from the Department of Biostatistics, Faculty of Health & Life Sciences, University of Liverpool, UK. GABO:mi from Munich, Germany, is the project management partner.
The European Research Program Horizon 2020
The European Union regularly announces research programs in order to develop and strenghten the European Research and Innovation Area by funding cross-border research projects. Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By fostering international collaboration in research and innovation, Horizon 2020 addresses the huge social challenges like fighting diseases, securing enery requirements or adapting to climate changes. It will support scientists all over the world to collaborate and find solutions for problems of social and global interest.
Dr. Patricia Marquardt | Max-Planck-Institut für molekulare Genetik
Yuan Chang and Patrick Moore win prize for the discovery of two cancer viruses
14.03.2017 | Goethe-Universität Frankfurt am Main
BMBF funding for diabetes research on pancreas chip
08.02.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
27.03.2017 | Earth Sciences
27.03.2017 | Life Sciences
27.03.2017 | Life Sciences